Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
Ibrutinib treatment in early-stage CLL delayed disease progression compared with placebo. However, with the given observation time and few deaths, no survival benefit was demonstrated. In the era of targeted therapies, watch and wait remains the standard of care irrespective of risk factors.
Authors
- Florian Simon (ORCID: https://orcid.org/0000-0002-2700-3717)
- Petra Langerbeins (ORCID: https://orcid.org/0000-0002-6654-0304)
- Timo Behlendorf
- Paula Cramer (ORCID: https://orcid.org/0000-0003-4046-9922)
- Clemens‐Martin Wendtner (ORCID: https://orcid.org/0000-0003-2866-2260)
- Stephan Stilgenbauer (ORCID: https://orcid.org/0000-0002-6830-9296)
- Marcel Reiser (ORCID: https://orcid.org/0000-0002-0457-7793)
- Holger Klaproth
- Eugen Tausch (ORCID: https://orcid.org/0000-0002-9503-1226)
- Holger Hebart (ORCID: https://orcid.org/0000-0003-4536-9955)
- Steffen Dörfel
- Anna‐Maria Fink (ORCID: https://orcid.org/0000-0002-7669-7890)
- Mark‐Oliver Zahn (ORCID: https://orcid.org/0000-0002-0528-5311)
- Andreas De Block (ORCID: https://orcid.org/0000-0002-7927-8210)
- Pascal Nieper (ORCID: https://orcid.org/0000-0003-0607-3561)
- Martina Stauch
- Ursula Vehling‐Kaiser
- Werner Freier (ORCID: https://orcid.org/0000-0002-0046-6471)
- Moritz Fürstenau (ORCID: https://orcid.org/0000-0002-6593-0140)
- Kirsten Fischer (ORCID: https://orcid.org/0009-0006-6169-9152)
- Christina Balser
- Sandra Robrecht (ORCID: https://orcid.org/0000-0001-8848-6655)
- Rüdiger Liersch
- Michael J. Eckart
- Michael J. Hallek (ORCID: https://orcid.org/0000-0002-7425-4455)
- Rudolf Schlag
- Lothar Müller (ORCID: https://orcid.org/0000-0001-9252-4650)
- Othman Al‐Sawaf (ORCID: https://orcid.org/0000-0001-9895-0570)
- Christof Schneider (ORCID: https://orcid.org/0000-0001-9719-7345)
- Barbara F. Eichhorst (ORCID: https://orcid.org/0000-0001-9990-6918)
- Ulrich Hauch
- Peter Staib
- Manfred Hensel
- Karl‐Anton Kreuzer
- Bernhard Heinrich (ORCID: https://orcid.org/0000-0002-9334-1335)
- Tobias Gaska
Institutions
- University of Hildesheim (DE)
- Universität Hamburg (DE)
- Philipps University of Marburg (DE)
- University of Cologne (DE)
- Universität Ulm (DE)
- Universitätsklinikum Erlangen (DE)
- Düsseldorf University Hospital (DE)
- Sankt-Antonius-Hospital Eschweiler (DE)
- Universitätsklinikum Würzburg (DE)
- Brüderkrankenhaus St. Josef Paderborn (DE)
- University Hospital Cologne (DE)
- Onkozentrum Dresden (DE)
- Heinrich Heine University Düsseldorf (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1200/jco.24.00975
- Citations
- 10
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 4.38